Figure 5.

Summary of lung function changes over time for ivacaftor and comparator patients, (A) US CFFPR and (B) UK CFR. *Within-group; ^†Between-group. ^aIncludes all patients followed from 2011 through 2014 (regardless of availability of ppFEV₁ values in a given analysis year). ^bCalculations of change from baseline performed on patients with non-missing ppFEV₁ values in 2011 and 2014 (n=636 for ivacaftor; n=2854 for comparator). ^cIncludes all patients followed from 2012 through 2014. ^dCalculations of change from baseline performed on patients with non-missing ppFEV₁ values in 2012 and 2014 (n=250 for ivacaftor; n=1211 for comparator). CFFPR, Cystic Fibrosis Foundation Patient Registry; CFR, Cystic Fibrosis Registry; ppFEV₁, per cent predicted FEV₁.